Piper Sandler Reiterates Neutral on Elanco Animal Health, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Westenberg has reiterated a Neutral rating on Elanco Animal Health (ELAN) and increased the price target from $12 to $18.

March 12, 2024 | 2:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has maintained a Neutral rating on Elanco Animal Health but raised the price target from $12 to $18.
The increase in price target from $12 to $18 by a reputable analyst firm like Piper Sandler suggests a positive outlook on ELAN's stock value in the short term. Although the rating remains Neutral, the significant raise in price target could lead to increased investor interest and potentially a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 90